Skip to main content

Prospective Multi-Institutional Validation of a Practical Eculizumab Dosing Regimen for Transplant-Associated Thrombotic Microangiopathy in Children and Young Adults

In brief

Fixed eculizumab dosing tables pass prospective validation in 23 transplant patients

In children and young adults with high-risk transplant-related microangiopathy, weight-, bleeding-status- and treatment-phase-based dosing tables accurately predicted drug levels and complement control in an independent 23-patient study. The approach could help centers dose eculizumab without real-time biomarker monitoring, but the study does not establish whether the tables improve clinical outcomes.

Journal
Transplantation and cellular therapy (Q1)
Published
19 November 2026
Study design
Prospective / inception cohort
Evidence level
Level 2, Moderate (CEBM 2b)
Authors
Sonata Jodele, Kana Mizuno, Christopher E Dandoy, Alexander A Vinks, Ashely Teusink-Cross, Paibel Aguayo-Hiraldo, et al.
PMID
43057679
DOI
10.1016/j.jtct.2026.11.040

Why clinicians should know about it

  • Picked for Hematology (paper of the day, 22 November 2026): Prospectively validates practical eculizumab dosing for post-transplant TA-TMA
  • Picked for Immunology and Allergy (paper of the day, 20 November 2026): Prospectively validated complement inhibitor dosing for transplant-associated microangiopathy

Abstract

BACKGROUND: Transplant-associated thrombotic microangiopathy (TA-TMA) is a life-threatening complication following hematopoietic stem cell transplantation (HSCT). Terminal complement blocker eculizumab improves outcomes in high-risk complement-mediated TA-TMA, but HSCT recipients exhibit accelerated and highly variable drug clearance, particularly in the presence of gastrointestinal (GI) bleeding, making dosing regimens developed for other complement-mediated diseases inadequate. Although individualized dosing using real-time complement biomarker monitoring is effective, these resources are unavailable at most transplant centers, limiting optimized implementation of eculizumab therapy. OBJECTIVES: The goal of this study was to translate extensive real-time PK/PD-guided eculizumab dosing experience into practical, fixed dosing regimens presented in an easy-to-use table format for HSCT recipients with high-risk TA-TMA, enabling implementation at centers without access to real-time complement biomarker and drug pharmacokinetic (PK) monitoring. We sought to derive weight- and bleeding status-based dosing recommendations for the loading, induction, and maintenance phases of therapy, determine the treatment duration required for most patients, identify dosing schedules with the lowest drug utilization, and prospectively validate this dosing framework in an independent multi-institutional clinical study. STUDY DESIGN: Eculizumab dosing requirements were derived using PK/PD model-informed simulations integrated with real-time drug concentration, complement biomarker, and clinical outcome data from 64 consecutively treated patients with high-risk TA-TMA (PK64 cohort). Weight- and bleeding status-based fixed dosing regimens were developed for the loading, induction, and maintenance phases of therapy and prospectively validated in an independent multi-institutional interventional study of 23 patients receiving early eculizumab therapy for high-risk TA-TMA with multiorgan dysfunction syndrome (PK23 cohort). RESULTS: A total of 87 HSCT recipients with high-risk complement-mediated TA-TMA were included. PK/PD modeling identified distinct dosing requirements according to body weight and gastrointestinal bleeding status, established more granular weight categories than currently approved eculizumab dosing, defined phase-specific loading, induction, and maintenance regimens, and identified drug-utilization-optimized dosing schedules with equivalent predicted clinical outcomes. The final product was a set of fixed eculizumab dosing regimens summarized in practical table format for routine clinical use without real-time complement biomarker monitoring. The derived dosing framework was then prospectively validated in an independent, multi-institutional interventional study (ClinicalTrials.gov NCT03518203; IND 136738; NIH R01 HD093773). Validation confirmed that the derived dosing framework accurately predicted phase-specific dosing requirements, pharmacokinetic behavior, and complement control across independent patient populations, supporting the reproducibility and clinical applicability of the proposed dosing tables. CONCLUSIONS: This study translates extensive real-time PK/PD experience into practical model-informed fixed eculizumab dosing regimens presented in an easy-to-use table format for HSCT-associated TA-TMA. The framework provides weight-, bleeding status-, and treatment phase-specific guidance that can be implemented at centers without real-time complement biomarker monitoring. It is applicable to eculizumab and eculizumab biosimilars and supports biologically informed treatment discontinuation once complement-mediated disease activity has resolved, helping avoid unnecessarily prolonged therapy.

Abstract as published, via PubMed.

View on PubMedFull text at the publisherOpen in the app

For healthcare professionals. The summary is generated by AI from the published abstract, and the evidence level is assigned automatically from the study design on the Oxford CEBM hierarchy. Neither is medical advice. Read the full paper before changing practice.